Cartilage oligomeric matrix protein-induced complement activation in systemic sclerosis by unknown
Otteby et al. Arthritis Research & Therapy 2013, 15:R215
http://arthritis-research.com/content/15/6/R215RESEARCH ARTICLE Open AccessCartilage oligomeric matrix protein-induced
complement activation in systemic sclerosis
Kaisa E Otteby1, Emelie Holmquist1, Tore Saxne2, Dick Heinegård2ˆ, Roger Hesselstrand2 and Anna M Blom1*Abstract
Introduction: Complexes between cartilage oligomeric matrix protein (COMP) and the complement activation
product C3b have been found in the circulation of patients with rheumatoid arthritis and systemic lupus
erythematosus. In systemic sclerosis (SSc) COMP expression in the skin is upregulated both in lesional and
non-lesional skin, which is also reflected in an increased amount of circulating COMP. We investigated the presence
of COMP-C3b complexes in serum and skin biopsies of patients with SSc.
Methods: The presence of COMP and COMP-C3b complexes in the serum of 80 patients with limited cutaneous
SSc (lcSSc, n = 40) and diffuse cutaneous SSc (dcSSc, n = 40) and 97 healthy controls was measured by ELISA and
correlated to different clinical parameters. Samples were collected both at baseline and after three to five years to
assess longitudinal changes in COMP-C3b complex levels. Furthermore, skin biopsies from seven patients with
dcSSc and three healthy controls were analyzed for expression of COMP and deposition of C3b and IgG.
Results: Serum levels of COMP-C3b were found to be elevated in both dcSSc and lcSSc compared to healthy
controls and decreased at the second measurement in patients on immunosuppressive therapy. No co-localization
of COMP and C3b was found in the skin biopsies, indicating that the COMP-C3b complexes are formed upon
release of COMP into the circulation.
Conclusion: COMP-C3b complexes are found in the serum of patients with SSc. The lack of co-localization between
COMP and C3b in the skin suggests that COMP does not drive complement activation in the skin in SSc.Introduction
Systemic sclerosis (SSc) is a multi-organ disease character-
ized by fibrosis of the skin and internal organs as well as
vasculopathy [1]. SSc is generally divided into two subsets
based on the extent of skin fibrosis and organ involvement;
diffuse cutaneous SSc (dsSSc) or limited cutaneous SSc
(lcSSc). Fibrosis in SSc is associated with extensive depos-
ition of extracellular matrix components, such as collagen
type I, III [2] and V [3] in the affected tissue. Several stud-
ies have also reported the presence of cartilage oligomeric
matrix protein (COMP) in both lesional and non-lesional
skin biopsies [4-6] as well as expression in cultured dermal
fibroblasts from SSc patients [4,7]. Others have also found
COMP in healthy human skin where it was suggested to
regulate the structure of the collagen I network [8]. COMP,* Correspondence: anna.blom@med.lu.se
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reproduction in any medium, provided the oralso known as Thrombospondin-5, is a pentameric protein
involved in the assembly and stabilization of collagen net-
works in extracellular matrices [9,10]. COMP was origin-
ally purified as a component of cartilage [11], but is also
expressed in tendon [12]. COMP is found at elevated levels
in serum during SSc, most likely as a result of release from
the affected tissues, and serum COMP has been shown to
correlate with the modified Rodnan skin score (mRSS) in-
dicating that the amount of COMP released into the circu-
lation is dependent on disease activity and/or severity
related to fibrosis [13]. Serum COMP has been found to be
higher in patients with dcSSc than in patients with lcSSc
and may further be elevated by SSc-related arthritis [5,14].
Serum COMP levels in early disease have in addition been
shown to predict mortality in SSc, possibly explained by
the more frequent and severe internal organ involvement
in patients with dcSSc [15]. Although COMP is also
expressed in vascular smooth muscle cells [16], serum
COMP levels in SSc have mostly reflected features of fibro-
sis and not vascular complications.Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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SSc. Infiltrates of activated T-cells and macrophages are
found in skin lesions early in disease [17,18]. Inflammation
is often less pronounced in SSc than in other rheumatic
diseases but increased serum levels of pro-inflammatory
cytokines, such as tumor necrosis factor, interferon-γ and
interleukin-6 can be found in SSc patients and are influ-
enced by both disease duration and the autoantibody pro-
file [19,20]. Autoantibodies can be found in the majority of
patients, most commonly against centromere, topoisomer-
ase I, U3/U1-RNP and RNA polymerase III [21], although
the contribution of such antibodies to disease pathology is
still unknown. Activation of the complement system is also
likely to occur, as complement activation products C3d, Ba
[22] and C4a [23] can be found in the circulation of pa-
tients during active disease. Furthermore, C5b-9 can be
found in skin lesions in both early and advanced SSc [24].
A decreased expression of the complement inhibitors
decay accelerating factor and membrane cofactor protein
in the vascular endothelium has also been observed in SSc,
which might contribute to vascular damage and further to
fibrosis [25].
We showed previously that COMP can activate the
complement system, which occurs exclusively through the
alternative pathway [26]. Furthermore, as an indication of
in vivo complement activation by COMP, complexes be-
tween COMP and the complement activation product
C3b can be found in the serum of patients with SSc [27].
Whether these complexes are formed in the skin lesions
or in serum after COMP-release is, however, still unclear.
By studying extracts of skin biopsies from SSc patients, it
has been demonstrated that COMP in the skin comprises
an approximately 56 kDa region of the C-terminus [13].
Interestingly, the C-terminus activates complement [26]
and it also stimulates autoantibody production in patients
with rheumatoid arthritis [28]. Therefore we hypothesized
that COMP induces complement activation in the skin at
the site of COMP-expression.
In this study we set out to verify the presence of
COMP-C3b complexes in the serum of SSc patients using
a larger patient cohort and to study the relation of
COMP-C3b to different clinical parameters as well as to
examine presence of complexes longitudinally. We have
further investigated the presence and co-localization of
COMP and deposited complement components in the
skin of SSc patients.
Methods
Patients
Serum was collected from 80 patients with SSc who all
fulfilled the American College of Rheumatology (ACR)
criteria for SSc [29]. The disease was classified as dcSSc
(n = 40) or lcSSc (n = 40) based on the extent of skin in-
volvement [30]. Samples were collected within 3 years ofdisease onset, which was defined as the first non-Raynaud’s
manifestation. A second sample was collected from each
patient 3 to 5 years after the first sampling. Of the 80 pa-
tients, 20 were included in a previous cross-sectional study
on COMP-C3b in SSc [27].
Serum was furthermore collected from 97 healthy volun-
teers with no history of rheumatologic disease, from Lund
and Malmö. All serum samples were retrieved at a stan-
dardized fashion (non-fasting) and were stored at −80°C
after centrifugation. Further characteristics of the patients
and controls are described in Table 1.
Informed written consent was obtained from all partici-
pants involved in the study and permission was obtained
from the regional ethical review board for Lund Univer-
sity. In the case of the patient under 18 years of age, oral
consent was obtained from the parents for taking the first
blood sample as part of clinical diagnostic routine as well
as for storage of the sample for use in the research project,
and informed written consent from the patient herself was
obtained at the time point of the second sample when she
was an adult. These procedures were fully in line with the
ethics regulations in Sweden at the time of sampling.
Fluorescence microscopy
Punch-biopsies, 3 or 4 mm in size were collected from the
dorsal part of the right or left forearm, 2 to 4 cm proximal
of the wrist. Skin samples were fixed in 4% formaldehyde,
dehydrated with ethanol, embedded in paraffin and sliced
to 4.5-μm sections. After mounting onto Superfrost Plus
glass slides, samples were de-paraffinized and rehydrated
as described [31]. Antigen retrieval was performed by heat-
ing samples to 100°C for 5 minutes in 0.01 M Na-citrate
buffer, pH 6.0. Between each step of the staining, samples
were washed three times with PBS and all antibodies were
diluted in 1% BSA in PBS. After blocking sections with 1%
BSA in PBS, sections were incubated for 1 h at room
temperature (RT) with a monoclonal antibody against C3/
C3b (ab11871, Abcam, Cambridge, United Kingdom), or
an antigen affinity-purified rabbit anti-COMP antibody
(homemade). Following washing, sections were incubated
with Alexa Fluor-conjugated secondary antibodies
(A21445, A1108, A21235, Invitrogen, Carlsbad, CA, USA)
for 1 h at RT. Nuclear staining was performed by incubating
samples with propidium iodide for 10 minutes at RT. Sam-
ples were analyzed and images obtained using a Zeiss LCM
510 confocal microscope. Co-localization of target mole-
cules was evaluated using the CoLocalizer Express software
(CoLocalization Research Software, Japan) and signal inten-
sity in the tissues was measured using the ImageJ software.
Measurement of serum COMP and COMP-C3b
Serum COMP-levels were measured using a commercially
available COMP-kit (AnaMar, Lund, Sweden). Serum
COMP-C3b was measured on maxisorp plates (Nunc,
Table 1 Description of patients and controls
lcSSc baseline lcSSc second sample dcSSc baseline dcSSc second sample Controls
Number 40 40 40 40 97
Age, years median (range) 47.5 (16 to 77) 50 (21 to 81) 51.5 (22 to 77) 56 (26 to 80) 45 (23 to 74)
Gender, female:male 33:7 33:7 28:12 28:12 67:30
COMP, U/l median (range) 9.3 (4.2 to 27.9) 9.7 (3.9 to 15.8) 16.0 (6.2 to 37.2) 10.9 (5.0 to 30.0) 7.0 (3.2 to 12.1)
Disease duration, years median (range) 1.4 (0.2 to 3.0) 5.0 (3.2 to 7.1) 1.0 (0.3 to 3.0) 4.6 (3.3 to 7.5) Not applicable
COMP-C3b, AU median (range) 2.5 (0.4 to 6.4) 1.9 (0.8 to 6.1) 2.3 (0.2 to 3.8) 1.7 (0.7 to 4.0) 0.6 (0 to 4.4)
mRSS median (range) 5.0 (2.0 to 19.0) 3.0 (0 to 15.0) 22.5 (3.0 to 43.0) 12.5 (0 to 33.0) Not applicable
CRP, mg/l median (range) 5.0 (0.8 to 79.0) 4.0 (0 to 72.0) 9.9 (0.8 to 91.0) 4.9 (0.6 to 74.0) nd
ERS, mm/h median (range) 11.0 (2.0 to 92.0) 14.0 (3.0 to 60.0) 18.0 (4.0 to 50.5) 20.0 (2.0 to 66.0) nd
Immunosuppressant AZA:CYC:MTX:MMF 1:1:1:0 12:0:2:3 1:2:2:0 12:1:2:8
Prednisolon, yes:no 7:32 11:28 13:25 13:25
ANA, positive:negative 31:9 29:11 nd
ENA, positive:negative 10:30 10:30 nd
ACA, positive:negative 10:30 1:39 nd
ATA, positive:negative 3:32 7:29 nd
5 unknown 4 unknown
ARA, positive:negative 0:27 6:25 nd
13 unknown 9 unknown
lcSSc, limited cutaneous systemic sclerosis; dcSSc, diffuse cutaneous systemic sclerosis; ACA, anti to centromere antibody; COMP: cartilage oligomeric matrix pro-
tein; AU, arbitrary units; mRSS, modified Rodnan skin score; CRP, C-reactive protein; nd, not determined; ERS, erythrocyte sedimentation rate; AZA, azathioprine;
CYC, cyclophosphamide; MTX, methotrexate; MMF, mycophenolate mofetil; ANA, antinuclear antibody; ENA, extractable nuclear antigen antibody; ATA,
anti-topoisomerase antibody; ARA, anti-RNA polymerase III antibody.
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monoclonal antibody against COMP (home made) at a
concentration of 5 μg/ml in 50 mM Hepes pH 7.4 with
2 mM CaCl2 overnight at +4°C. The plates were washed
with 50 mM Tris–HCl, 150 mM NaCl, 0.1% Tween-20,
pH 8.0 between each step in the assay. Plates were
blocked using 1% BSA (Millipore, Billerica, MA, USA)
diluted in 50 mM Hepes, pH 7.4 with 2 mM CaCl2
(blocking buffer) to prevent unspecific interactions.
Serum samples were diluted 1:70 in 50 mM Hepes
pH 7.4, 150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2 with
50 μg/ml BSA, added to the wells and incubated for 2 h
at RT. A biotinylated polyclonal anti-C3 antibody
(CC7761, Sigma, St. Louis, MO, USA) was diluted in
blocking buffer and incubated in the wells for 1 h at RT
followed by a streptavidin-HRP conjugate (21130,
Pierce, Thermo Scientific, Rockford, IL, USA). The
plates were developed with o-phenylenediamine (OPD)
substrate (Dako, Glostrup, Denmark) and H2O2 and
the absorbance at 490 nm was measured using a Cary
50 MPR microplate reader (Varian, Palo Alto, CA,
USA). Each sample was analyzed in duplicate and
values obtained from the uncoated wells were sub-
tracted from values obtained from antibody-coated
wells. Obtained readings were then normalized against
an internal control sample rendering data presented as
arbitrary units (AU).Statistical analysis
The statistical significance of differences between groups
was measured using the Kruskal-Wallis test with Dunn’s
post hoc test or the Wilcoxon matched-pairs signed rank
test, where appropriate. Two-parameter correlations were
performed using Spearman’s correlation test. The signifi-
cance of co-localization of staining in tissue was evaluated
using Manders’ overlap coefficient.
Results
Levels of COMP-C3b complexes are elevated in SSc
Both COMP and COMP-C3b levels were found to be el-
evated in the serum of SSc patients compared to healthy
controls (P <0.0001) corroborating our earlier results
(Figure 1A and Table 1). There was no difference in
serum COMP-C3b levels between patients with dcSSc and
lcSSc, whereas patients with dcSSc had significantly higher
serum COMP levels than patients with lcSSc (P <0.0001)
(Figure 1B). COMP-C3b levels were not related to the
autoantibody profile of the patient (not shown). There was
a decrease in COMP-C3b in both dcSSc and lcSSc between
the first and the second sample obtained (Figure 1C), how-
ever, this decrease was significant only for patients who
were introduced to immunosuppressive treatment between
the first and second sampling (dcSSc: P = 0.007 with im-
munosuppression, P = 0.188 with no immunosuppression;
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Figure 1 Cartilage oligomeric matrix protein (COMP)-C3b and COMP in patients and controls. Serum COMP-C3b (A) and COMP (B) were
measured in patients with diffuse cutaneous systemic sclerosis (dcSSc) (n = 40), limited cutaneous systemic sclerosis (lcSSc) (n = 40) and healthy controls
(n = 97). The longitudinal changes in COMP-C3b (C) and COMP (D) was measured. Statistical significance of differences was measured using the Kruskal-
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Figure 2 Correlation of cartilage oligomeric matrix protein (COMP)-C3b with clinical parameters. Correlation between serum COMP-C3b
and modified Rodnan skin score (mRSS) (A and B), CRP (C and D) and COMP (E and F) was measured in patients with disease duration less than
3 years. rs, Spearman’s correlation coefficient; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis.
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affect the serum COMP-C3b levels in either patient group.
Baseline COMP was high in the dcSSc-group and de-
creased significantly during follow up (Figure 1D). Patients
with lcSSc, however, displayed normal COMP levels both
at baseline and at follow up and consequently no significant
reduction was observed.Levels of COMP-C3b complexes correlate with disease
activity in dcSSc
COMP-C3b correlated with mRSS in the dcSSc group at
baseline (rs = 0.4226, P = 0.0066) (Figure 2A) when a num-
ber of dcSSc patients had rather high mRSS values, but not
at the later time point (Table 2). No correlation was found
between these parameters in the lcSSc group (Figure 2B)
or when studying all SSc-patients together (not shown).
There was furthermore a correlation between COMP-C3b
and CRP (rs = 0.7574, P <0.0001) in the dcSSc group in the
first time-point sample (Figure 2C). These data show that
serum COMP-C3b, at least to some extent, is related to dis-
ease activity and inflammation, but mainly in the dcSSc
subset of patients. The change in COMP-C3b between the
first and second sample correlated weakly to the change in
C-reactive protein (CRP) (rs = 0.231, P = 0.043), but not to
the change in mRSS (rs = 0.007, P = 0.953). This indicates
that COMP-C3b is more related to the general inflamma-
tory response in the patients than to the actual skin fibrosis.
The change in COMP, however, correlated to the change in
mRSS (rs = 0.362, P = 0.001) in agreement with earlier re-
sults [13].Table 2 Correlation of COMP-C3b with clinical parameters
Spearman r P-value
mRSS all 0.1611 0.1534
dcSSc 0.4226 0.0066
lcSSc 0.0366 0.8226
CRP all 0.3930 0.0003
dcSSc 0.7574 <0.0001
lcSSc −0.0110 0.9464
COMP all 0.0089 0.9374
dcSSc 0.1803 0.2655
lcSSc −0.1623 0.3172
C3 all 0.2055 0.0749
dcSSc 0.3145 0.0579
lcSSc 0.0172 0.9171
C4 all 0.2184 0.0581
dcSSc 0.3499 0.0338
lcSSc 0.0935 0.5714
mRSS, modified Rodnan skin score; CRP, C-reactive protein; COMP, cartilage
oligomeric matrix protein; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc,
limited cutaneous systemic sclerosis.As we have observed earlier, COMP-C3b did not correl-
ate with COMP, either in the whole SSc group or in any of
the subgroups (Figure 2E-F). There was no correlation be-
tween COMP-C3b and the serum C3-levels in SSc pa-
tients, but a weak positive correlation was found between
COMP-C3b and C4 (Table 2). Only five of the patients
had C3 levels lower than 80% of normal at baseline,
whereas 14 patients had C4-levels lower than 80% of nor-
mal, indicating that inflammation in SSc does not cause
any major complement consumption.
C3b is deposited in SSc skin lesions
The expression of COMP in skin lesions of SSc patients
has been demonstrated in several studies [4-6], where it
was found both in papillary dermis as well as in deeper
dermal layers. In healthy skin, COMP has been found
mainly in the papillary dermis [8]. We evaluated COMP
staining in skin biopsies from seven patients with dcSSc
and three healthy controls. We found variable COMP
staining throughout the tissue in patient samples. Two
of the control samples were negative for COMP and the
third showed a barely detectable staining (Figure 3).
C3b deposition was observed to a very low degree in pa-
tient samples and was in most cases more pronounced in
the papillary dermis than in the reticular dermis (Figure 3).
One of the three healthy controls also showed weak C3b
staining, both in the papillary and reticular dermis. There
was no statistically significant co-localization between
COMP and C3b in the tissue, however, in two of the pa-
tients approximately 30% of the COMP and C3b stains
overlapped. The amount of C3b deposition in the skin did
not correlate with the local skin score.
As SSc is associated with autoantibody production, we
evaluated whether autoantibodies deposit on COMP in
the tissue. Similar to COMP, the IgG staining showed large
heterogeneity between the patients and overlapped weakly
with the COMP staining in only two samples (not shown).
Discussion
We have confirmed in a large patient cohort that COMP-
C3b levels are elevated in patients with SSc compared to
healthy controls. The fact that there is no difference in
serum COMP-C3b between patients with dcSSc and lcSSc
is interesting, as these groups have quite different disease
phenotypes and the systemic inflammatory component is
more pronounced in dcSSc. The higher COMP levels seen
in dcSSc are most likely a reflection of more extensive fi-
brotic skin involvement, as the COMP found in the circu-
lation in SSc patients is thought to be released from the
skin. Supporting this, we found a positive correlation be-
tween serum COMP and mRSS (rs = 0.5808, P <0.0001). As
we detect no correlation between COMP-C3b and COMP,
we can hypothesize that only certain fragments of released
COMP are able to activate complement or that a certain
Figure 3 Cartilage oligomeric matrix protein (COMP) does not co-localize with C3b in the skin. Skin biopsies from seven patients with
diffuse cutaneous systemic sclerosis (dcSSc) and three healthy controls were analyzed for COMP (green) and C3b (red). Nuclear staining is shown
in blue. COMP staining was variable in the patients but mainly negative in the controls. Three patients and one control are shown as an example.
Upper row, patient with dcSSc for 2 years, no current treatment; second row, patient with dSSc for 13 years, no current treatment; third row:
patient with dcSSc for 2 years, one year of treatment with mycophenolate mofetil; fourth row, healthy control. The scale bars indicate 100 μm.
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the case also in other diseases, such as rheumatoid arthritis,
where no correlation was found between serum COMP
and COMP-C3b [27]. We found a correlation between
COMP-C3b and mRSS and CRP specifically in the dcSSc
subset of patients but not in lcSSc patients. This indicates
that COMP-C3b is more closely related to the disease activ-
ity and inflammation in patients with dcSSc. Interestingly,
COMP-C3b still decreased longitudinally in both subsets ofpatients upon immunosuppressive treatment, showing that
even though COMP-C3b is not directly correlated to indi-
vidual parameters of inflammation, it may still act as a
measure of disease activity, even in the lcSSc goup. As the
change in COMP-C3b correlated only weakly to the change
in CRP, we can hypothesize that even though both parame-
ters measure inflammation, other as yet unknown factors
affect the formation of COMP-C3b complexes that may
not be detected by general inflammatory measures.
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found, most likely due to the fact that no apparent comple-
ment consumption was observed in the patients. In the
dcSSc subset we saw a weak positive correlation between
COMP-C3b and C4. Such positive correlation has previ-
ously been seen in patients with systemic lupus erythe-
matosus [27]. Reasons for such a correlation remain
speculative, but we can at least conclude that the forma-
tion of COMP-C3b complexes does not drive activation
and therefore consumption of the classical complement
pathway components.
Most skin biopsies of dcSSc patients studied showed
COMP-staining, corroborating results published by others.
Since we found very weak C3b staining in the skin of these
patients, and the deposited C3b did not seem to co-
localize with COMP, we can conclude that COMP in the
skin does not drive measurable complement activation.
Therefore, we can assume that the COMP-C3b complexes
found in SSc patients do not originate from the skin but
are formed in the blood after COMP is released into the
circulation. It is likely that COMP needs to be cleaved or
processed in a specific way or have a specific conformation
for it to be able to trigger C3b-deposition, and that this
does not occur until COMP is detached from the skin.
These alterations might occur due to a specific inflamma-
tory environment with local production of proteases and
therefore may be down-regulated when the inflammatory
reaction is diminished. This could explain the reduction of
serum COMP-C3b in SSc patients at follow up. As the C-
terminal globular domain of COMP, which is the domain
responsible for complement activation [26], is engaged in
multiple interactions in tissues, it is also possible that
COMP needs to detach from its interacting partners in
the tissue for it to be able to stimulate complement.
Conclusion
Complexes between COMP and C3b are found in the cir-
culation of both patients with dcSSc and lcSSc, although
their levels relate more to individual inflammatory param-
eters in dcSSc. These complexes seem to form when
COMP is released from the skin into the circulation and
therefore it seems that COMP itself does not drive com-
plement activation and deposition in the skin in SSc.Abbreviations
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